Results 161 to 170 of about 27,075 (224)

Combination olaparib and cyclophosphamide cancer therapy exacerbates ovarian reserve depletion in mice with conditional loss of <i>Brca1</i> in oocytes. [PDF]

Front Endocrinol (Lausanne)
Cao Y, Jalil ZA, Mu X, Stringer JM, Zerafa N, Winship AL, Hutt KJ.   +6 more
europepmc   +1 more source

Procyanidin C1 combined with olaparib induces senescence in BRCA1-proficient breast cancer cells. [PDF]

Am J Cancer Res
Ren C, Fu C, Chen X, Yang R, He J, Gao A, Su Q, Teng X, Xu J.   +8 more
europepmc   +1 more source

QSAR-Guided Virtual Screening and Molecular Dynamics Reveal Olaparib as a Repurposing Lead Against α-Synuclein Aggregation. [PDF]

Int J Mol Sci
Abdelsayed M, Boulaamane Y.
europepmc   +1 more source

STN1 upregulation promotes PARPi resistance in BRCA2-deficient cancer cells via replication fork protection and suppression of ssDNA gap formation. [PDF]

NAR Cancer
Laghari ZA, Li N, Gayybov S, Wang QE, Chai W.   +4 more
europepmc   +1 more source

Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation. [PDF]

Signal Transduct Target Ther
Camps-Fajol C, Minguillón J, Surrallés J.   +2 more
europepmc   +1 more source

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression. [PDF]

J Immunother Cancer
Santiago-Sanchez G, Rosato F, Fabian KP, Padget MR, Lee JM, Karzai F, Schlom J, Gulley JL, Hamilton DH, Lee JK, Pruitt MR, Bayliffe A, Su Z, Moisan J, Katragadda M, Hodge JW.   +15 more
europepmc   +1 more source

Combination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer. [PDF]

Exp Hematol Oncol
Chiappa M, Villa V, Sias F, Grasselli C, Sala L, Canesi S, Marabese M, Mason S, Dibitetto D, Fruscio R, Damia G.   +10 more
europepmc   +1 more source

From Oxidative Stress to Bioenergetic Remodeling: Translational Value and Clinical Implications of Exogenous ATP in PARP Inhibitor-Associated Liver Injury [Letter]. [PDF]

Drug Des Devel Ther
Shang M, Ge X.
europepmc   +1 more source

A 5-Azetidinyl BODIPY-Olaparib Conjugate for PARP-Targeted Nuclear and Orthotopic Oral Tumor Imaging. [PDF]

ChemMedChem
Yan K, Qi H, Dong X, Zhao W.
europepmc   +1 more source

Molecular Characterization of PARP Inhibitor Response Reveals Co-Targeting Strategies in Advanced Prostate Cancer. [PDF]

Cancers (Basel)
Gonzalez BC, Karthikeyan A, Moore LA, Bhaumik A, Sandoval E, Hardy M, Davis RR, Batra N, Lucchesi CA, Gao AC, Li H, McPherson JD, Dall'Era M, Lombard AP.   +13 more
europepmc   +1 more source